Home

ErgMS is the clinical trial we are current carrying on. In this trial, we are aiming to recruit adults with risks of metabolic syndrome, supplement our volunteer’s ergothioneine and investigate the potential health benefits of 12 weeks supplementation. Specifically, we will investigate if ergothioneine supplementation would alter markers of oxidative stress, inflammation, blood platelet function, liver function, and metabolism in the blood.

ErgMS_Participant Information Sheet V3.0 August 2021

Our volunteers will be asked to take a single capsule daily for 12 weeks. Participants will be asked to visit the university study site three times: at baseline (at the beginning of the study), after 6 weeks, and after 12 weeks of supplementation. This will be to complete questionnaires, provide blood samples, and have their height, weight, waist circumference and blood pressure measured in the university visiting.

participant timeline

Volunteers will receive measurement of body weight, height, waist circumference and blood pressure and assessments of oxidative stress, inflammatory markers and liver health. Potential benefits may be improvements in metabolic syndrome risk factors.

Risks to participating are considered minimal and the supplemental doses of ergothioneine (5/30 mg/day) being tested are considered safe under these conditions. These doses are well below the safety limit (800 mg/kg bodyweight per day—e.g. 56,000mg/day for a 70kg adult) established by the European Food Safety Authority in 2016.

Due to the COVID-19 pandemic and for the safety of our potential participants and researchers, a face covering (covering both mouth and nose) is mandatory when entering the building. All the equipment (bays/chairs, tables, beam scale, tape, blood pressure monitor etc.) in the human study room will be disinfected with the disinfectant, chemgene, before and after the visit. Also, the study room will be aired for at least 1 hour between participants.